Development and preliminary validation of the Scleroderma Support Group Leader Self-efficacy Scale
- PMID: 35382120
- PMCID: PMC8892874
- DOI: 10.5301/jsrd.5000260
Development and preliminary validation of the Scleroderma Support Group Leader Self-efficacy Scale
Abstract
Support groups are an important resource for people living with systemic sclerosis (SSc; scleroderma). Peer support group leaders play an important role in the success and sustainability of SSc support groups, but face challenges that include a lack of formal training. An SSc support group leader training program could improve leader self-efficacy to carry out important leadership tasks, including the management of group dynamics. However, no measures exist to assess self-efficacy among SSc support group leaders. The objective of this study was to develop and provide preliminary evidence on the reliability and validity of the Scleroderma Support Group Leader Self-efficacy Scale (SSGLSS). The SSGLSS was administered to two sets of SSc support group leaders from North America, Europe, and Australia. Study 1 participants (n = 102) completed the SSGLSS only. Study 2 participants (n = 55) completed the SSGLSS and the Oldenburg Burnout Inventory (OLBI). For both studies, we evaluated internal consistency reliability using Cronbach's coefficient alpha. Convergent validity was assessed in Study 2 using Pearson correlations of the SSGLSS with the OLBI exhaustion and disengagement subscales. Cronbach's alpha was 0.96 in Study 1 and 0.95 in Study 2. Consistent with our hypotheses, there was a small negative correlation between SSGLSS scores and the OLBI exhaustion subscale (r = -0.25, p<0.01) and a moderate negative correlation between SSGLSS scores and the disengagement subscale (r = -0.38, p<0.01). These results suggest that the SSGLSS is a reliable and valid measure of self-efficacy for carrying out support group leadership tasks.
Keywords: Patient-reported outcome measures; Psychometrics; Scleroderma; Self-help groups; Social support; Systemic.
© The Author(s) 2017.
Conflict of interest statement
Disclosures: Financial support: The research was supported by the Scleroderma Society of Ontario and the Canadian Initiative for Outcomes in Rheumatology Care. Conflict of interest: None of the authors has financial interest related to this study to disclose.
References
-
- Scleroderma Seibold J.. In: Harris ED, Budd RC, Firestein GS, et al., eds. Kelley’s textbook of rheumatology. 7th ed. Philadelphia, PA: Elsevier. 2005;1279-1308.
-
- Mayes M. Systemic sclerosis: clinical features. In: Klippel JH, Stone JH, Crafford LJ, White PH, eds. Primer on the rheumatic diseases. 13th ed. New York, NY: Springer. 2008;343-350.
-
- Scleroderma Society of Canada. Find a support group. http://www.scleroderma.ca/Support/Find-A-Support-Group.php. Accessed September 2, 2017.
-
- Scleroderma Foundation. Support groups. http://www.scleroderma.org/site/PageServer?pagename=ts_support_groups#.W.... Accessed September 2, 2017.
-
- Davison KP, Pennebaker JW, Dickerson SS. Who talks? The social psychology of illness support groups. Am Psychol. 2000;55(2):205-217. - PubMed
LinkOut - more resources
Full Text Sources